Literature DB >> 25563723

Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C.

Jennifer C Lai1, Dolores M Shoback, Jacob Zipperstein, Blanca Lizaola, Samuel Tseng, Norah A Terrault.   

Abstract

BACKGROUND: Whether chronic HCV, a disease characterized by systemic inflammation, impacts bone mineral density (BMD) independent of cirrhosis is unknown. AIM: We aimed to evaluate the association between BMD, systemic inflammation, and markers of bone turnover in chronic HCV without cirrhosis.
METHODS: Non-cirrhotics, 40-60 years old, with chronic HCV underwent measurement of: (1) BMD by dual-energy X-ray absorptiometry scan and (2) serum markers of systemic inflammation and bone turnover. By Chi-squared or t test, we compared those with normal versus low BMD.
RESULTS: Of the 60 non-cirrhotics, 53 % were female and 53 % Caucasian. Mean (SD) age was 53.3 years (5.7), total bilirubin 0.7 mg/dL (0.3), creatinine 0.8 mg/dL (0.2), and body mass index 28.4 kg/m(2) (6.5). Low BMD was observed in 42 %: 30 % had osteopenia, 12 % had osteoporosis. Elevated tumor necrosis factor α, interleukin-6, and C-reactive protein levels were found in 26, 32, and 5 %, respectively, but did not differ by BMD group (p > 0.05). Patients with low BMD had higher serum phosphorus (4.1 vs. 3.5 mg/dL) and pro-peptide of type 1 collagen (P1NP; 73.1 vs. 47.5 ng/mL) [p < 0.05], but similar bone-specific alkaline phosphatase, serum C-telopeptide, and parathyroid hormone levels.
CONCLUSIONS: Low BMD is prevalent in 40- to 60-year-old non-cirrhotics with chronic HCV, but not associated with systemic inflammatory markers. Elevated P1NP levels may help to identify those at increased risk of bone complications in this population. Chronic HCV should be considered a risk factor for bone loss, prompting earlier BMD assessments in both men and women.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25563723      PMCID: PMC4797945          DOI: 10.1007/s10620-014-3507-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  37 in total

1.  Osteoporosis and skeletal fractures in chronic liver disease.

Authors:  T Diamond; D Stiel; M Lunzer; M Wilkinson; J Roche; S Posen
Journal:  Gut       Date:  1990-01       Impact factor: 23.059

2.  Generalised bone loss in patients with early rheumatoid arthritis.

Authors:  A K Gough; J Lilley; S Eyre; R L Holder; P Emery
Journal:  Lancet       Date:  1994-07-02       Impact factor: 79.321

Review 3.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1994

4.  Osteoporosis or low bone mass at the femur neck or lumbar spine in older adults: United States, 2005-2008.

Authors:  Anne C Looker; Lori G Borrud; Bess Dawson-Hughes; John A Shepherd; Nicole C Wright
Journal:  NCHS Data Brief       Date:  2012-04

5.  Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis?

Authors:  C C Chen; S S Wang; F S Jeng; S D Lee
Journal:  J Gastroenterol Hepatol       Date:  1996-05       Impact factor: 4.029

6.  Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2013-09-03       Impact factor: 25.391

7.  Screening for osteoporosis: U.S. preventive services task force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2011-01-17       Impact factor: 25.391

8.  Prevalence and predictors of low bone mineral density in males with ulcerative colitis.

Authors:  Nabeel Khan; Ali M Abbas; Rawaa M Almukhtar; Amna Khan
Journal:  J Clin Endocrinol Metab       Date:  2013-04-17       Impact factor: 5.958

9.  Chronic hepatitis. An update on terminology and reporting.

Authors:  K P Batts; J Ludwig
Journal:  Am J Surg Pathol       Date:  1995-12       Impact factor: 6.394

Review 10.  High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review.

Authors:  M A C van der Weijden; T A M Claushuis; T Nazari; W F Lems; B A C Dijkmans; I E van der Horst-Bruinsma
Journal:  Clin Rheumatol       Date:  2012-06-16       Impact factor: 2.980

View more
  14 in total

1.  Risk factors associated with invasive orthopaedic interventions in males with haemophilia enrolled in the Universal Data Collection program from 2000 to 2010.

Authors:  P Tobase; H Lane; A-E-A Siddiqi; J M Soucie; R Ingram-Rich; S Ward; J C Gill
Journal:  Haemophilia       Date:  2018-06-29       Impact factor: 4.287

Review 2.  HIV and Bone Complications: Understudied Populations and New Management Strategies.

Authors:  Michael T Yin; Todd T Brown
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

Review 3.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

Review 4.  Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture.

Authors:  Roger Bedimo; Naim M Maalouf; Vincent Lo Re
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

5.  Direct‑acting antiviral treatment decreases serum undercarboxylated osteocalcin in male patients with chronic hepatitis C.

Authors:  Tatsuki Ichikawa; Mio Yamashima; Shinobu Yamamichi; Makiko Koike; Yusuke Nakano; Tetsurou Honda; Hiroyuki Yajima; Osamu Miyazaki; Yasutaka Kuribayashi; Tomonari Ikeda; Takuma Okamura; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2022-09-01

6.  Bone density and microarchitecture in hepatitis C and HIV-coinfected postmenopausal minority women.

Authors:  M T Yin; A RoyChoudhury; K Nishiyama; T Lang; J Shah; S Olender; D C Ferris; C Zeana; A Sharma; B Zingman; M Bucovsky; I Colon; E Shane
Journal:  Osteoporos Int       Date:  2018-02-01       Impact factor: 4.507

7.  Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.

Authors:  Juan Berenguer; Elena Rodríguez-Castellano; Ana Carrero; Miguel A Von Wichmann; Marta Montero; María J Galindo; Josep Mallolas; Manuel Crespo; María J Téllez; Carmen Quereda; José Sanz; Carlos Barros; Cristina Tural; Ignacio Santos; Federico Pulido; Josep M Guardiola; Rafael Rubio; Enrique Ortega; María L Montes; Juan J Jusdado; Gabriel Gaspar; Herminia Esteban; José M Bellón; Juan González-García
Journal:  Hepatology       Date:  2017-06-22       Impact factor: 17.425

Review 8.  Risk Factors and Management of Osteoporosis Post-Transplant.

Authors:  Karthik Kovvuru; Swetha Rani Kanduri; Pradeep Vaitla; Rachana Marathi; Shiva Gosi; Desiree F Garcia Anton; Franco H Cabeza Rivera; Vishnu Garla
Journal:  Medicina (Kaunas)       Date:  2020-06-19       Impact factor: 2.430

9.  Association between Mycobacterium avium complex lung disease and serum vitamin D status, antimicrobial peptide levels, and bone mineral density.

Authors:  Kohei Fujita; Yutaka Ito; Tsuyoshi Oguma; Tadashi Mio; Akio Niimi; Toyohiro Hirai
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

10.  Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients.

Authors:  Roger Bedimo; Minhee Kang; Pablo Tebas; Edgar T Overton; Kimberly Hollabaugh; Grace McComsey; Debika Bhattacharya; Christopher Evans; Todd T Brown; Babafemi Taiwo
Journal:  AIDS Res Hum Retroviruses       Date:  2015-11-24       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.